← Research library

Thymopentin as add-on treatment for severe atopic dermatitis

Randomized study in people · 1994

What was studied
39 patients at least two years old with severe eczema involving at least 20% of the skin surface. Arm-level sample sizes are unavailable in the abstract.
Main finding
The 39-person double-blind trial reported significantly greater improvement at week 12 with thymopentin as an adjunct to usual eczema care.

Reported findings and study design

Findings described in words

Randomized double-blind placebo-controlled add-on trial with serial clinical assessments.

Population or model 39 patients at least two years old with severe eczema involving at least 20% of the skin surface. Arm-level sample sizes are unavailable in the abstract.

Dose, route and schedule

Thymopentin 50 mg subcutaneously three times a week for 12 weeks or matching placebo. Both groups could use topical corticosteroids and oral antihistamines.

Protocol source ↗ · Original indexed abstract and publisher record, including the earlier presentation note.

Results · Original indexed abstract and publisher record, including the earlier presentation note.
MeasureResultComparison, timing and statistics
Clinical improvement in severe eczemaSignificantly greater with thymopentin plus usual care than with placebo plus usual careWeek 12
Reported drug-related adverse effectsNone reported in the abstract.

Source for these results ↗ · Reviewed 2026-11-15

Study limitations and source details

Study limitations

  • The abstract gives no arm-level score changes or group sizes. The 1992 and 1993 conference presentations cited by the paper are earlier presentations of this work.

Source details

Original indexed abstract and publisher record, including the earlier presentation note.

Sources checked

Citation

Randomized trialEnglish abstract

M. J. Stiller, J. L. Shupack, C. Kenny, L. Jondreau, D. E. Cohen, N. A. Soter. Thymopentin as add-on treatment for severe atopic dermatitis Journal of the American Academy of Dermatology. 1994;30(4):597–602.

Study source ↗ · DOI 10.1016/S0190-9622(94)70068-0 · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards